Again, we are all 'assuming' which makes this all worse for
Again, we are all 'assuming' which makes this all worse for everyone. Until Management or the SEC or someone at the OTC comes out and tells us what exactly is going on, everything is a guess. However what we do know is some clowns dumped the stock down to .04 something at one point and it has never recovered.
Also again, it has been proven that sales of Excellegan has been in the millions so that product is a valid product. We have also had a paper on their Cancer testing for a 10 year study that shows it works. Both are valid. We have deals which are valid. We have a 500+ million worth of NUGENERX that sits out there. That is valid. So, there is something there. Products and science do exist. These are all facts that regardless of management, they do exist and have some impact to companies that can use them or at the very least they are viable to the needs outside, they just need to get out there.
If the Board of Directors ever gets a backbone or Joe ever decides he needs to step up or down and let someone take the reigns, maybe just maybe they can bring things to light. On the otherhand, if there is someone with deep pockets who believes these products and the science is worth anything, then we might have something as well.
And as I have said so many times, time will tell if we see anything from the products or the science or the shareholders will see anything positive out of all of this. In the end, it's a wait and see game for the most part and Joe if simply not helping matters at all and neither is the Board of Directors .
4
Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...
Continue Reading
Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...
Continue Reading
Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...
Continue Reading
myKaarma Offers Time and Convenience Boost with Wash Option When was the last time a car dealership didn't have folks lined up waiting for a wash? Dragging out your car's service longer than a Sunday sermon. But today, myKaarma, the folks behind dealership customer interaction magic, cracked open another bottle of convenience with their latest offering: off-site,...
Continue Reading
Big Changes Ahead for Home Franchise Concepts It's a fresh dawn over at Home Franchise Concepts, and Cory Lyons has been tapped to lead four pivotal brands as their new Brand President. Now, if you're looking at this lineup—Kitchen Tune-Up, Bath Tune-Up, The Tailored Closet, and PremierGarage—you know there's more than just nails and hammers involved. Lyons isn't just...
Continue Reading
Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...
Continue Reading
Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...
Continue Reading
Introducing a Heavy-Duty Defender for Lab Systems When it comes to safeguarding central laboratory vacuum systems, you can bet there’s more at play than meets the eye. Mass-Vac, Inc., steps up and doesn't mess around with their latest innovation—the MV Multi-Trap® Vacuum Inlet Trap. Climbing aboard in November 2026, this stout guardian against contamination is out to...
Continue Reading
AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...
Continue Reading
AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...
Continue Reading
ws Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles
